Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Primary Care
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Answer from: at Community Practice
Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.
Sign in or Register to read more
23325
Related Questions
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Will you incorporate the use of tirzepatide in the management of patients with OSA?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
What is your preferred laboratory test to assess treatment response or infection resolution in patients with bacterial pneumonia?
What role might depemokimab play in the stepwise approach to asthma management, especially for patients who have previously failed other biologic therapies?